Market news

Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.

Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can translate into more durable growth, but the two healthcare giants are entering very different stages of their turnarounds. Pfizer is rebuilding around newer medicines as COVID revenue declines and generic and biosimilar competition approaches. Medtronic, meanwhile, is […]

Medtronic plc’s (NYSE:MDT) investment thesis rests on accelerating growth across its key innovation platforms. CEO Geoff Martha noted ongoing strength in core segments such as Cranial and Spinal Technologies, Surgical, and Cardiac Rhythm Management. This comes along with encouraging momentum in high-growth opportunities such as Hugo robotic surgery, Symplicity, Altaviva, Affera, and Stealth AXiS. Read […]

Medtronic (NYSE:MDT) agreed a US$700 million partnership with Cornerstone Robotics to distribute the Sentire surgical system globally. The Cornerstone deal expands Medtronic's presence in surgical robotics beyond its existing platforms into a new multi-country distribution arrangement. Medtronic also partnered with Sonus Microsystems on AI-powered wearable ultrasound technology for maternal health programs in Kenya. There is more to Medtronic than the Cornerstone and Sonus partnerships...

Truist starts MiniMed (MMED) at Buy with a $29 target (~41% upside), citing new launches and diabetes tech share gains. Read more here.

Medtronic (MDT) reached $89.3 at the closing of the latest trading day, reflecting a -1.62% change compared to its last close.

Medtronic buy rating: $106.33 price target, 17% upside + 3% yield. Q1 beats and raised guidance. Click for more on MDT stock.

Medtronic plc (NYSE:MDT) drew a broad round of price-target increases after its fiscal 2027 first-quarter results, but Wall Street remains divided over whether accelerating growth can support a meaningful re-rating of the stock. The acceleration follows an earlier debate over whether Medtronic (MDT) is finally becoming a turnaround story. Bull Case: Growth Is Broadening Mizuho […]

Medtronic delivered solid Q1 FY27 results, with organic revenue growth of ~7%, and raised full-year guidance to 7.25–7.75%. Learn more about MDT stock here.

Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil

Wall Street doesn't appear to be giving Medtronic credit for its improving results.

Medtronic is rated a Buy, citing Q1 2027 beat, raised FY2027 EPS guidance, solid debt metrics, and 15% undervalued. Read the latest analysis on MDT stock here.

Medtronic (NYSE:MDT) received FDA clearance for its LigaSure vessel-sealing device on the Hugo robotic surgery system in the U.S. The authorization allows LigaSure to be used on the Hugo platform for soft-tissue procedures in U.S. hospitals and surgical centers. The cleared configuration integrates a widely used vessel-sealing tool with Medtronic’s robotic-assisted surgery platform for general surgery use. The new FDA clearance for LigaSure on Hugo is one more factor to weigh alongside the...

Reuters reported that Medtronic plc (NYSE:MDT) raised the lower end of its fiscal 2027 profit forecast and its revenue growth outlook on September 1, banking on strong demand for heart devices used in complex cardiovascular procedures. The Ireland-based company raised the lower end of its adjusted per-share profit forecast to $5.94 from $5.90, keeping the […]

In September 2026, Sonus Microsystems Inc. announced a collaboration with Medtronic plc to integrate its AI-powered Sonus Patch wearable ultrasound platform with Medtronic’s Acute Care & Monitoring technology, testing a non-invasive system in Kenya to screen and triage pregnant women at risk of early-onset preeclampsia under a Gates Foundation-funded study. This project not only expands Medtronic’s use of AI and remote monitoring, but also shows how its technology can be adapted for...

Medtronic (NYSE:MDT) Chief Financial Officer Thierry Piéton said the medical-device maker’s focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are supporting its recent growth momentum. Speaking with Peter Harrison of Morgan Stanley Investment Bankin

Partnership will pair Medtronic vital-sign monitoring with Sonus’s ultrasound AI platform in field studies, funded by the Gates FoundationVANCOUVER, British Columbia and LAFAYETTE, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Sonus Microsystems today announced a collaboration with Medtronic, the global leader in healthcare technology, to integrate the Sonus Patch™, an AI-powered wearable ultrasound platform, with technology from the Acute Care & Monitoring operating unit at Medtronic. The collabora

Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

Jim Cramer called Medtronic plc (NYSE:MDT) a “quandary” on the September 8 episode of Mad Money, as he said: At the same time, there’s some tremendous healthcare companies in bull market mode… Here’s one that’s a quandary, Medtronic. Medtronic, the medical device company, shocked us with a big upside surprise and a major increase in […]

On September 1, Medtronic (NYSE:MDT) reported fiscal 2027 first-quarter results that blew past its own guidance, with revenue of $9.8 billion and organic growth of 13.7%. An extra selling week included in the quarter, which ended July 31, added roughly $570 million to that figure. Still, even stripping that out, management called it the strongest […]

Medtronic plc (NYSE:MDT) entered fiscal 2027 expecting solid growth. One quarter later, strong demand for its cardiovascular devices has given management enough confidence to raise that outlook. The company increased its organic revenue growth forecast and lifted the lower end of its adjusted earnings range after beating quarterly expectations. Its cardiovascular business was the standout, […]

Medtronic has a historically high 3% yield and is just two years away from becoming a Dividend King.

MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

Medtronic (NYSE:MDT) executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies. Speaking at the Wells Fargo Healthcare Conference, Chairman and Chief

MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.

Motley Fool Press Release.

While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Medtronic’s cardiac ablation solutions, a sub-segment of its electrophysiology business, was the strongest performer in Q1 with YoY growth of 29.5%.